Bellevue Obesity Solutions I2 EUR

Reference Data

ISIN LU1725387622
Valor Number
Bloomberg Global ID
Fund Name Bellevue Obesity Solutions I2 EUR
Fund Provider Bellevue Asset Management AG Zürich, Switzerland
Phone: +41 44 267 67 00
E-Mail: info@bellevue.ch
Web: www.bellevue.ch
Fund Provider Bellevue Asset Management AG
Representative in Switzerland Waystone Fund Services (Switzerland) SA
Lausanne
Phone: 0041213111781
Distributor(s) Bank am Bellevue AG
Küsnacht
Phone: +41 44 267 67 67
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth by investing at least two thirds of the net assets in a portfolio of carefully chosen shares and preference shares of companies whose business is directed towards the prevention and treatment of overweight or obesity and their secondary conditions or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries.
Peculiarities

Fund Prices

Current Price * 167.43 EUR 31.10.2024
Previous Price * 169.09 EUR 30.10.2024
52 Week High * 178.97 EUR 30.08.2024
52 Week Low * 146.70 EUR 28.11.2023
NAV * 167.43 EUR 31.10.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 37,861,081
Unit/Share Assets ***
Trading Information SIX

Performance

YTD Performance +10.37% 29.12.2023
31.10.2024
YTD Performance (in CHF) +11.73% 29.12.2023
31.10.2024
1 month -1.98% 30.09.2024
31.10.2024
3 months -3.75% 31.07.2024
31.10.2024
6 months +1.69% 30.04.2024
31.10.2024
1 year +11.95% 31.10.2023
31.10.2024
2 years -9.09% 31.10.2022
31.10.2024
3 years -12.48% 02.11.2021
31.10.2024
5 years -6.84% 15.06.2021
31.10.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 8.62%
UnitedHealth Group Inc 6.43%
Novo Nordisk AS Class B 6.10%
Johnson & Johnson 4.72%
Thermo Fisher Scientific Inc 3.79%
Amgen Inc 3.39%
AstraZeneca PLC ADR 3.25%
Danaher Corp 2.99%
Boston Scientific Corp 2.87%
Novartis AG Registered Shares 2.82%
Last data update 30.09.2024

Cost / Risk

TER 1.40%
TER date 29.01.2021
Performance Fee *** 0.00%
PTR
Max. Management Fee *** 0.80%
Ongoing Charges *** 1.36%
SRRI ***
SRRI date *** 30.09.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)